Bio-Rad Laboratories, Inc. $BIO Shares Newly Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) in the third quarter, HoldingsChannel reports. The fund bought 4,605 shares of the medical research company’s stock, valued at approximately $1,739,000.

Other hedge funds have also modified their holdings of the company. Dimensional Fund Advisors LP lifted its position in Bio-Rad Laboratories by 1.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,089,323 shares of the medical research company’s stock worth $303,637,000 after acquiring an additional 12,251 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Bio-Rad Laboratories by 57.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 233,227 shares of the medical research company’s stock worth $68,478,000 after acquiring an additional 85,393 shares during the period. Hound Partners LLC grew its position in Bio-Rad Laboratories by 125.9% in the first quarter. Hound Partners LLC now owns 97,724 shares of the medical research company’s stock valued at $27,241,000 after acquiring an additional 54,456 shares in the last quarter. Hosking Partners LLP grew its position in Bio-Rad Laboratories by 1.1% in the third quarter. Hosking Partners LLP now owns 95,472 shares of the medical research company’s stock valued at $36,061,000 after acquiring an additional 1,042 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Bio-Rad Laboratories in the second quarter valued at approximately $17,690,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BIO has been the topic of a number of analyst reports. Weiss Ratings upgraded shares of Bio-Rad Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. Royal Bank Of Canada upped their target price on shares of Bio-Rad Laboratories from $390.00 to $440.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Zacks Research raised shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Wells Fargo & Company raised their price target on shares of Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Finally, Citigroup lifted their price target on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $366.67.

Get Our Latest Stock Report on BIO

Bio-Rad Laboratories Trading Up 0.1%

NYSE:BIO opened at $366.60 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.37 and a current ratio of 3.18. Bio-Rad Laboratories, Inc. has a one year low of $236.73 and a one year high of $396.23. The business’s 50-day simple moving average is $373.01 and its 200 day simple moving average is $317.45. The stock has a market cap of $9.86 billion, a price-to-earnings ratio of 9.65 and a beta of 1.06.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.23 by $0.42. Bio-Rad Laboratories had a return on equity of 3.58% and a net margin of 39.45%. The firm had revenue of $656.40 million during the quarter, compared to the consensus estimate of $649.94 million. During the same quarter in the prior year, the business posted $2.26 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was up .5% on a year-over-year basis. As a group, sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP Courtney C. Enloe sold 902 shares of the company’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $386.17, for a total value of $348,325.34. Following the transaction, the executive vice president directly owned 750 shares of the company’s stock, valued at $289,627.50. This represents a 54.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP James Barry sold 1,400 shares of the stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $385.63, for a total value of $539,882.00. Following the transaction, the executive vice president owned 625 shares of the company’s stock, valued at approximately $241,018.75. This trade represents a 69.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,221 shares of company stock valued at $1,247,049 in the last three months. Corporate insiders own 30.34% of the company’s stock.

About Bio-Rad Laboratories

(Free Report)

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.

Further Reading

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.